График акции Equillium, Inc.
Расширенный график
Простой график
О компании Equillium, Inc.
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. подробнее| IPO date | 2018-10-11 |
|---|---|
| ISIN | US29446K1060 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | https://equilliumbio.com |
| Цена ао | 0.758 |
| Изменение цены за день: | -4.79% (0.4863) |
|---|---|
| Изменение цены за неделю: | -1.49% (0.47) |
| Изменение цены за месяц: | -39.87% (0.77) |
| Изменение цены за 3 месяца: | -33.86% (0.7) |
| Изменение цены за полгода: | -57.13% (1.08) |
| Изменение цены за год: | -74.13% (1.79) |
| Изменение цены за 3 года: | -85.02% (3.09) |
| Изменение цены за 5 лет: | -88.25% (3.94) |
| Изменение цены с начала года: | -22.58% (0.598) |
|
|
Недооценка
|
Эффективность
|
|||||||||||||||||||||||||||||||||||||
Дивиденды
|
Долг
|
Импульс роста
|
|||||||||||||||||||||||||||||||||||||
| Институционалы | Объем | Доля, % |
|---|---|---|
| Decheng Capital Management III (Cayman), LLC | 4447308 | 12.61 |
| Decheng Capital LLC | 4447308 | 12.61 |
| Vanguard Group Inc | 836930 | 2.37 |
| Cota Capital Management, LLC | 562278 | 1.59 |
| Tang Capital Management, LLC | 400000 | 1.13 |
| JP Morgan Chase & Company | 350031 | 0.99 |
| Renaissance Technologies, LLC | 347500 | 0.99 |
| Geode Capital Management, LLC | 172387 | 0.49 |
| Commonwealth Equity Services, LLC | 100000 | 0.28 |
| Callan Capital LLC | 99688 | 0.28 |
| Руководитель | Должность | Оплата | Год рождения |
|---|---|---|---|
| Mr. Daniel Mark Bradbury | Executive Chairman | 158k | 1961 (64 года) |
| Mr. Bruce D. Steel C.F.A. | Co-Founder, President, CEO & Director | 779.87k | 1966 (59 лет) |
| Ms. Christine Zedelmayer M.B.A., P.M.P. | Senior VP & COO | 553.73k | 1970 (55 лет) |
| Dr. Stephen Connelly Ph.D. | Chief Scientific Officer & Director | 571.32k | 1982 (43 года) |
| Mr. Jason A. Keyes | Chief Financial Officer | N/A | 1971 (54 года) |
| Mr. Michael Moore | Vice President of Investor Relations & Corporate Communications | N/A | |
| Dr. Matthew Ritter Ph.D. | Senior Vice President of Corporate Development | N/A | |
| Mr. Joel M. Rothman | Chief Development Officer | N/A | 1969 (56 лет) |
| Penny Tom | Senior VP of Finance & Principal Accounting Officer | N/A |
Адрес: United States, La Jolla. CA, 2223 Avenida De La Playa - открыть в Google картах, открыть Яндекс картах
Сайт: https://equilliumbio.com
Сайт: https://equilliumbio.com
